Sphingolipids in Cancer - 1st Edition - ISBN: 9780128142233

Sphingolipids in Cancer, Volume 140

1st Edition

Serial Volume Editors: Charles E. Chalfant Paul Fisher
Hardcover ISBN: 9780128142233
Imprint: Academic Press
Published Date: 9th August 2018
Page Count: 410
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.

Key Features

  • Provides information on cancer research, with this release focusing on sphingolipids
  • Offers outstanding and original reviews on a range of cancer research topics
  • Serves as an indispensable reference for researchers and students alike

Readership

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.

Table of Contents

  1. Mechanisms of ceramide-dependent cancer cell death
  2. Rose Nganga, Natalia Oleinik and Besim Ogretmen

  3. Sphingolipids as regulators of autophagy and endocytic trafficking
  4. Megan M. Young and Hong-Gang Wang

  5. Role and function of sphingomyelin biosynthesis in the development of cancer
  6. Giovanni D’Angelo, Sitapriya Moorthi and Chiara Luberto

  7. Neutral sphingomyelinases in cancer: friend or foe?
  8. Christopher J. Clarke

  9. Ceramide and exosomes: a novel target in cancer biology and therapy
  10. Ahmed Elsherbini and Erhard Bieberich

  11. Sphingolipids at the crossroads of NAFLD and senescence
  12. Mariana Nikolova-Karakashian

  13. Ceramide signaling and p53 pathways
  14. Kristen Jeffries and Natalia Krupenko

  15. The role of ceramide 1-phosphate in tumor cell survival and dissemination
  16. Antonio Gomez-Muñoz

  17. The onus of sphingolipid enzymes in cancer drug resistance
  18. Samy A.F. Morad and Myles C. Cabot

  19. Interdiction of sphingolipid metabolism revisited: focus on prostate cancer
  20. Christina Voelkel-Johnson, James S. Norris and Shai White-Gilbertson

  21. Targeting sphingosine kinases for the treatment of cancer
  22. Clayton S. Lewis, Christina Voelkel-Johnson and Charles D. Smith

  23. Novel sphingolipid-based cancer therapeutics in the personalized medicine era
  24. Jeremy Shaw, Pedro Costa-Pinheiro, Logan Patterson, Kelly Drews, Sarah Spiegel and Mark Kester

  25. Side effects in cancer therapy: are sphingolipids to blame?

Falak Patel and Stefka D. Spassieva

Details

No. of pages:
410
Language:
English
Copyright:
© Academic Press 2018
Published:
Imprint:
Academic Press
Hardcover ISBN:
9780128142233

About the Serial Volume Editor

Charles E. Chalfant

Professor Charles E. Chalfant heads up the Chalfant Laboratory and is the director of the Lipidomic Facility at Virgina Commonwealth University. The Chalfant laboratory is currently focused on two major areas of cell signaling and human pathophysiologies: 1) lipid and oncogenic regulation of alternative splicing; and 2) the regulation of eicosanoid synthesis in inflammation and cancer.

Affiliations and Expertise

Director of Lipidomics Facility, Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA

Paul Fisher

Paul B. Fisher, M.Ph., Ph.D., is an accomplished molecular biologist investigating the mechanisms involved in cancer development and progression in order to define improved methods for cancer prevention, detection and therapy. Fisher pioneered a powerful technique to study gene expression in specific tissues or cell types known as subtraction hybridization, which he has used to identify genes involved in many important and medically relevant physiological processes including cancer, neurodegeneration and infectious diseases. Studies in his laboratory focus on understanding the molecular and biochemical reasons for cancer development with a specific focus on understanding how cancers spread, a process called metastasis. The ultimate aim is to use this collected knowledge to bring new, more effective prevention techniques, diagnostic approaches and therapies from the laboratory bench to the patient’s bedside. This is epitomized by his studies involving mda-7/IL-24, a gene that was discovered in his laboratory and has displayed significant clinical efficacy in a phase 1 clinical trial when injected directly into advanced cancers using a form of viral gene therapy. Using a novel cancer terminator virus, Ad.5/3-CTV, that is designed to replicate only within cancer cells while delivering the immune-modulating and toxic mda-7/IL-24 gene, Fisher and his clinical colleagues are developing a clinical trial in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. Fisher has been consistently funded by the National Institutes of Health (NIH) over the past 35 years and is among the top 5 percent of NIH funded investigators during this period. He has published over 500 primary papers and reviews, served on numerous NIH study sections and government and private grant review panels and has over 55 issued patents. He is the recipient of multiple National Cancer Institute (NCI) Program Project Grants; investigator initiated R01 grants from the NIH, NCI and National Institute of General Medical Sciences (NIGMS); private foundation grants from the National Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation; and an Institutional Research and Academic Career Development Award from the NIH focusing on preparing students from groups underrepresented in the sciences for research careers. Fisher is Professor and Chair of the Department of Human and Molecular Genetics at the Virginia Commonwealth University (VCU) School of Medicine, Founding Director of the VCU Institute of Molecular Medicine and Thelma Newmeyer Corman Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center.

Affiliations and Expertise

VCU Institute of Molecular Medicine, VA, USA

Ratings and Reviews